Kalvista Pharmaceuticals Inc (KALV)

$15.25 +0.31 (2.07%)
Market Cap 828.45M
Revenue (ttm) 0.00
Net Income (ttm) -183.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,349,020
Avg Vol 1,432,366
Day's Range N/A - N/A
Shares Out 50.55M
Stochastic %K 3%
Beta -0.14
Analysts Strong Sell
Price Target $33.22

Company Profile

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formu...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 999 0075
Fax: 866 553 3269
Address:
55 Cambridge Parkway, Suite 901 East, Cambridge, United States
MilaGoldframe01
MilaGoldframe01 Jan. 14 at 3:07 PM
$KALV back in here.
0 · Reply
Carlito84
Carlito84 Jan. 14 at 2:52 PM
$KALV💩 stock
0 · Reply
Phyrodox
Phyrodox Jan. 13 at 10:23 PM
$KALV any news to warrant the drop?
0 · Reply
Carlito84
Carlito84 Jan. 13 at 8:56 PM
$KALV sold
0 · Reply
JFais
JFais Jan. 12 at 1:04 PM
$BCRX $601M in Orladeyo revenues for 2026 and still growing +37% yoy (impressive for a subpar drug!) Clearly shows the demand is there & + building the oral market for $KALV $PHVS
3 · Reply
MarkyT
MarkyT Jan. 10 at 6:46 PM
$KALV targets raised...
0 · Reply
MarkyT
MarkyT Jan. 10 at 6:43 PM
$KALV ..see how this moves on Monday
0 · Reply
MarkyT
MarkyT Jan. 10 at 6:42 PM
$KALV as far as I can guess, institutions shorted the news and used dark pools to counter any move up.. with an addition 1m added to the short float yesterday..
0 · Reply
MarkyT
MarkyT Jan. 9 at 8:47 PM
$KALV ...clearly, someone didn't want this breaking out today!!! tossers
0 · Reply
www_larval_com
www_larval_com Jan. 9 at 8:17 PM
Dur-dur look @ $KALV just shot 4% higher to 8% (~5Mv) a moment ago, 01/16 options, follow for more volatility.
0 · Reply
Latest News on KALV
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug

Jan 9, 2026, 9:56 AM EST - 5 days ago

KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug

KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

Jan 8, 2026, 4:05 PM EST - 5 days ago

KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

Dec 22, 2025, 6:00 AM EST - 23 days ago

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 24, 2025, 10:53 AM EST - 7 weeks ago

KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript

KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 1:41 PM EST - 2 months ago

KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

Nov 10, 2025, 4:30 PM EST - 2 months ago

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

Nov 6, 2025, 8:01 AM EST - 2 months ago

KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Nov 5, 2025, 7:00 AM EST - 2 months ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

Nov 3, 2025, 7:00 AM EST - 2 months ago

KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 30, 2025, 7:00 AM EDT - 2 months ago

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

Oct 6, 2025, 4:00 PM EDT - 3 months ago

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

Oct 6, 2025, 7:00 AM EDT - 3 months ago

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 7:00 AM EDT - 3 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

Oct 2, 2025, 7:00 AM EDT - 3 months ago

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

Sep 26, 2025, 7:00 AM EDT - 3 months ago

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

Sep 24, 2025, 10:52 PM EDT - 3 months ago

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

Sep 24, 2025, 4:01 PM EDT - 3 months ago

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

Sep 19, 2025, 7:00 AM EDT - 4 months ago

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript

Sep 11, 2025, 11:43 AM EDT - 4 months ago

KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

Sep 11, 2025, 7:00 AM EDT - 4 months ago

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Sep 10, 2025, 7:06 AM EDT - 4 months ago

KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

KalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 7, 2025, 10:12 PM EDT - 4 months ago

KalVista Pharmaceuticals, Inc. (KALV) Presents At Cantor Global Healthcare Conference 2025 Transcript

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

Sep 4, 2025, 7:05 AM EDT - 4 months ago

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

Aug 27, 2025, 7:00 AM EDT - 5 months ago

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

Aug 11, 2025, 4:05 PM EDT - 5 months ago

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

MGX

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

Aug 11, 2025, 7:00 AM EDT - 5 months ago

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

Jul 25, 2025, 8:00 AM EDT - 6 months ago

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

Jul 15, 2025, 4:05 PM EDT - 6 months ago

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

Jul 10, 2025, 7:00 AM EDT - 6 months ago

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning

Jul 8, 2025, 3:52 PM EDT - 6 months ago

KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning

US FDA approves KalVista Pharma's swelling disorder drug

Jul 7, 2025, 6:37 AM EDT - 6 months ago

US FDA approves KalVista Pharma's swelling disorder drug

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

Jul 7, 2025, 6:30 AM EDT - 6 months ago

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

Jun 26, 2025, 7:00 AM EDT - 7 months ago

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

Jun 16, 2025, 7:00 AM EDT - 7 months ago

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

US FDA extends review of KalVista's swelling disorder drug due to heavy workload

Jun 13, 2025, 4:41 PM EDT - 7 months ago

US FDA extends review of KalVista's swelling disorder drug due to heavy workload

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

Jun 13, 2025, 4:05 PM EDT - 7 months ago

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025

Jun 5, 2025, 7:00 AM EDT - 7 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

Jun 2, 2025, 7:00 AM EDT - 8 months ago

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 7:00 AM EDT - 8 months ago

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

May 22, 2025, 7:00 AM EDT - 8 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

Apr 30, 2025, 7:00 AM EDT - 9 months ago

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

KalVista: Poised For Rare Disease Transformation

Apr 12, 2025, 12:42 AM EDT - 9 months ago

KalVista: Poised For Rare Disease Transformation

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

Apr 8, 2025, 6:30 AM EDT - 10 months ago

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 10 months ago

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

Mar 25, 2025, 7:00 AM EDT - 10 months ago

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Mar 12, 2025, 7:00 AM EDT - 11 months ago

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Mar 10, 2025, 7:00 AM EDT - 11 months ago

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Mar 3, 2025, 7:00 AM EST - 11 months ago

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Feb 21, 2025, 7:00 AM EST - 11 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

Feb 10, 2025, 7:00 AM EST - 1 year ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

MilaGoldframe01
MilaGoldframe01 Jan. 14 at 3:07 PM
$KALV back in here.
0 · Reply
Carlito84
Carlito84 Jan. 14 at 2:52 PM
$KALV💩 stock
0 · Reply
Phyrodox
Phyrodox Jan. 13 at 10:23 PM
$KALV any news to warrant the drop?
0 · Reply
Carlito84
Carlito84 Jan. 13 at 8:56 PM
$KALV sold
0 · Reply
JFais
JFais Jan. 12 at 1:04 PM
$BCRX $601M in Orladeyo revenues for 2026 and still growing +37% yoy (impressive for a subpar drug!) Clearly shows the demand is there & + building the oral market for $KALV $PHVS
3 · Reply
MarkyT
MarkyT Jan. 10 at 6:46 PM
$KALV targets raised...
0 · Reply
MarkyT
MarkyT Jan. 10 at 6:43 PM
$KALV ..see how this moves on Monday
0 · Reply
MarkyT
MarkyT Jan. 10 at 6:42 PM
$KALV as far as I can guess, institutions shorted the news and used dark pools to counter any move up.. with an addition 1m added to the short float yesterday..
0 · Reply
MarkyT
MarkyT Jan. 9 at 8:47 PM
$KALV ...clearly, someone didn't want this breaking out today!!! tossers
0 · Reply
www_larval_com
www_larval_com Jan. 9 at 8:17 PM
Dur-dur look @ $KALV just shot 4% higher to 8% (~5Mv) a moment ago, 01/16 options, follow for more volatility.
0 · Reply
MarkyT
MarkyT Jan. 9 at 8:10 PM
$KALV wow wow wowwoooo... absolute thieves... news and 2 broker upgrades and your stock is down...97% institutional owners ship and 40%... pure manipulation... absolutely stinks
0 · Reply
pblegend66
pblegend66 Jan. 9 at 7:24 PM
$KALV this is being insanely manipulated. Shorts are trying not to lose their shirts
1 · Reply
MarkyT
MarkyT Jan. 9 at 5:54 PM
$KALV it'd have expected a little more movement on this in the morning, not moving much.. into close, hopefully see it ramp as folks read the analyst notes
0 · Reply
MilaGoldframe01
MilaGoldframe01 Jan. 9 at 3:34 PM
$KALV got stopped out at 18.20... on watch for now...
0 · Reply
JazzyJ03
JazzyJ03 Jan. 9 at 3:29 PM
$KALV
0 · Reply
topstockalerts
topstockalerts Jan. 9 at 2:29 PM
$KALV look who’s up.. ⬆️
0 · Reply
Avocado_smash
Avocado_smash Jan. 9 at 1:58 PM
$KALV
0 · Reply
520Degenerate
520Degenerate Jan. 9 at 1:57 PM
$KALV This is gonna explode. Sales haven’t even started in Japan yet and they seem to get approved everywhere they ask. Imagine if they could get 25-50% of the world’s market share?!!!
0 · Reply
Avocado_smash
Avocado_smash Jan. 9 at 1:57 PM
$KALV https://www.businesswire.com/news/home/20260108509630/en/KalVista-Pharmaceuticals-Provides-Update-on-Strong-EKTERLY-Launch-with-Preliminary-Fourth-Quarter-and-Full-Year-2025-Revenue-Results
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 9 at 1:42 PM
$KALV (+14.4% pre) KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart https://ooc.bz/l/89198
0 · Reply
TwongStocks
TwongStocks Jan. 9 at 1:42 PM
$KALV One item I missed from yesterday's PR. They intend to submit an NDA for pediatric patients (age 2-11) in Q3 2026. "With EKTERLY rapidly emerging as the preferred on-demand HAE treatment, we remain committed to making it accessible to all people living with HAE, including pediatric patients aged 2-11 years, where we expect to file a new drug application in the third quarter.”"
0 · Reply
Stocktoberfest
Stocktoberfest Jan. 9 at 12:59 PM
$KALV That was interesting yesterday.
0 · Reply